Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21275246 | 0.96 | SIRT6 (0.69) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL5132635 | 0.91 | SIRT6 (0.62) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL5005578 | 0.90 | SIRT6 (0.61) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL18277850 | 0.90 | SIRT6 (0.61) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL30935303 | 0.89 | SIRT6 (0.59) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL15961228 | 0.89 | SIRT6 (0.59) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL20568737 | 0.89 | SIRT6 (0.59) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL4717711 | 0.89 | SIRT6 (0.59) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL282130 | 0.86 | SIRT6 (0.60) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 | |
| SCHEMBL2972930 | 0.85 | SIRT6 (0.55) | SIRT6LMNAMAPTL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680095-B2 | Heterocycle compounds and uses thereof for the prevention or treatment of diseases involving formation of amyloid plaques and/or where a dysfunction of the APP metabolism occurs | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2014-03-25 | — | — | US | disclosed |
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | UNIVERSITE LILLE 1 - SCIENCES ET TECHNOLOGIES (FR) | 2012-11-08 | — | — | US | disclosed |
| EP-2513062-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | Institut National de la Santé et de la Recherche Médicale (FR) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073322-A1 | 7-CHLORO-QUINOLIN-4-AMINE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283256-A1 | NEW HETEROCYCLE COMPOUNDS AND USES THEREOF FOR THE PREVENTION OR TREATMENT OF DISEASES INVOLVING FORMATION OF AMYLOID PLAQUES AND/OR WHERE A DYSFUNCTION OF THE APP METABOLISM OCCURS | APP, BACE1, PSEN1 | SIRT6 640/4885LMNA 694/4885MAPT 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.